Peltzman revisited : quantifying 21st-century opportunity costs of food and drug administration regulation
Year of publication: |
2022
|
---|---|
Authors: | Mulligan, Casey B. |
Published in: |
The journal of law & economics. - Chicago, Ill. : Univ. of Chicago Press, ISSN 1537-5285, ZDB-ID 2035113-6. - Vol. 65.2022, S2, p. S355-S387
|
Subject: | Arzneimittel | Pharmaceuticals | Generika | Generic drugs | Arzneimittelrecht | Pharmaceutical law | Pharmaindustrie | Pharmaceutical industry | Kosten-Nutzen-Analyse | Cost-benefit analysis | USA | United States |
-
Peltzman Revisited : Quantifying 21st Century Opportunity Costs of FDA Regulation
Mulligan, Casey B., (2021)
-
The Objectives of the Fda's Office of Generic Drugs
Scott Morton, Fiona M., (2022)
-
Empirical evidence of risk penalties for NTI Drugs
Gentry, Elissa Philip, (2019)
- More ...
-
Uncertainty, redistribution, and the labor market since 2007
Mulligan, Casey B., (2014)
-
Transitional Dynamics in Two-Sector Models of Endogenous Growth
Mulligan, Casey B., (1992)
-
U.S. Money Demand: Surprising Cross-Sectional Estimates
Sala-i-Martin, Xavier, (1992)
- More ...